The Patient Voice in Neovascular Age-Related Macular Degeneration: Findings from a Qualitative Study

被引:6
|
作者
Talks, S. James [1 ]
Daien, Vincent [2 ]
Mitchell, Paul [3 ]
Aslam, Tariq [4 ,5 ]
Barratt, Jane [6 ]
Biberger, Anna [7 ]
Lamoureux, Ecosse L. [8 ,9 ]
Hirst, Ceri [10 ]
Sylvanowicz, Michelle [10 ]
Finger, Robert P. [11 ]
机构
[1] Newcastle Tyne Hosp NHS Fdn Trust, Newcastle Eye Ctr, Newcastle Upon Tyne, England
[2] Univ Hosp Montpellier, Dept Ophthalmol, Montpellier, France
[3] Univ Sydney, Westmead Inst Med Res, Sydney, NSW, Australia
[4] Manchester Royal Eye Hosp, Manchester, England
[5] Univ Manchester, Manchester, England
[6] Int Federat Ageing, Toronto, ON, Canada
[7] Cerner Enviza, Munich, Germany
[8] Singapore Eye Res Inst, Singapore, Singapore
[9] Duke NUS Med Sch, Singapore, Singapore
[10] Bayer Consumer Care AG, Basel, Switzerland
[11] Univ Bonn, Dept Ophthalmol, Bonn, Germany
关键词
nAMD; Anti-VEGF; Patient care; Communication; Adherence; Persistence; Emotion; ANTI-VEGF TREATMENT; GROWTH-FACTOR THERAPY; DEPRESSION; EXPERIENCE; OUTCOMES; ANXIETY;
D O I
10.1007/s40123-022-00631-7
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Introduction: Visual impairment resulting from diseases such as neovascular age-related macular degeneration (nAMD) may cause behavioural, environmental, psychological, and logistical challenges that could act as barriers to effective uptake and sustainability of treatment with anti-vascular endothelial growth factor agents (anti-VEGFs). Understanding emotions and experiences of patients with nAMD may help inform the determinants of adherence, and could contribute to improvements in ophthalmic outcomes and quality of life. Methods: Seventeen patients with nAMD receiving anti-VEGF injections were enrolled from three clinics: one each in France (n = 5), Germany (n = 6), and the UK (n = 6). Patients' health information and treatment characteristics were collected. Individual phone interviews were conducted by experienced health care interviewers. Transcripts were analysed thematically. Results: Patients (53% female) had a mean age of 77 years. Bilateral anti-VEGF injections were received by 24% (n = 4); and most (76%, n = 13) were adherent to their treatment. Patient emotions at diagnosis ranged from happiness at learning about the treatment for nAMD to being terrified of receiving an injection in the eye. Most patients mentioned feeling anxious and fearful before their first injection despite receiving reassurance. After the first injection, these feelings and apprehension abated for many, but not all. With the goal of maintaining the best possible vision, few (24%, n = 4) patients reported more than one missed appointment, and most had never considered stopping treatment. No patient reported additional assistance beyond family support; however, many had difficulties with recreational and domestic activities and had developed coping strategies. Conclusion: This study provides insights on patients' emotions related to their experience of nAMD and its management, highlighting the varying experiences between individuals. It shows the importance of the patient's voice when considering patient care and management, and how the nature and timing of interventions can improve the experience of living with and managing nAMD.
引用
收藏
页码:561 / 575
页数:15
相关论文
共 50 条
  • [31] Macular atrophy development in neovascular age-related macular degeneration
    Calugaru, Dan
    Calugaru, Mihai
    EUROPEAN JOURNAL OF OPHTHALMOLOGY, 2022, 32 (01) : NP307 - NP308
  • [32] Neovascular age-related macular degeneration presenting at extremities of age: a comparative study
    Alexander Rubowitz
    Saleh Esa
    Maayan Fradkin
    Elad Moisseiev
    Graefe's Archive for Clinical and Experimental Ophthalmology, 2020, 258 : 2399 - 2405
  • [33] Neovascular age-related macular degeneration presenting at extremities of age: a comparative study
    Rubowitz, Alexander
    Esa, Saleh
    Fradkin, Maayan
    Moisseiev, Elad
    GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2020, 258 (11) : 2399 - 2405
  • [34] Sociodemographic Factors in Neovascular Age-Related Macular Degeneration
    Patel, Samir N.
    Wu, Connie
    Obeid, Anthony
    Sivalingam, Meera
    Gervasio, Kalla
    Wibbelsman, Turner D.
    Levin, Hannah
    Xu, David
    Regillo, Carl D.
    Hsu, Jason
    Ho, Allen C.
    OPHTHALMOLOGY, 2020, 127 (02) : 280 - 282
  • [35] Deep Learning in Neovascular Age-Related Macular Degeneration
    Borrelli, Enrico
    Serafino, Sonia
    Ricardi, Federico
    Coletto, Andrea
    Neri, Giovanni
    Olivieri, Chiara
    Ulla, Lorena
    Foti, Claudio
    Marolo, Paola
    Toro, Mario Damiano
    Bandello, Francesco
    Reibaldi, Michele
    MEDICINA-LITHUANIA, 2024, 60 (06):
  • [36] Radiation therapy for neovascular age-related macular degeneration
    Petrarca, Robert
    Jackson, Timothy L.
    CLINICAL OPHTHALMOLOGY, 2011, 5 : 57 - 63
  • [37] Gene Therapies for Neovascular Age-Related Macular Degeneration
    Pechan, Peter
    Wadsworth, Samuel
    Scaria, Abraham
    COLD SPRING HARBOR PERSPECTIVES IN MEDICINE, 2015, 5 (07):
  • [38] Innovative therapies for neovascular age-related macular degeneration
    Al-Khersan, Hasenin
    Hussain, Rehan M.
    Ciulla, Thomas A.
    Dugel, Pravin U.
    EXPERT OPINION ON PHARMACOTHERAPY, 2019, 20 (15) : 1879 - 1891
  • [39] SUBFOVEAL NEOVASCULAR LESIONS IN AGE-RELATED MACULAR DEGENERATION
    BLOOM, SM
    ARCHIVES OF OPHTHALMOLOGY, 1993, 111 (07) : 900 - 901
  • [40] Vitreomacular Adhesion and Neovascular Age-Related Macular Degeneration
    Simpson, Andrew R. H.
    Petrarca, Robert
    Jackson, Timothy L.
    SURVEY OF OPHTHALMOLOGY, 2012, 57 (06) : 498 - 509